-+ 0.00%
-+ 0.00%
-+ 0.00%

Akeso says press release available on Phase II dosing of AK146D1 with ivonescimab in advanced NSCLC

PUBT·07/20/2026 05:32:50
Listen to the news
Akeso says press release available on Phase II dosing of AK146D1 with ivonescimab in advanced NSCLC
  • Akeso published a press release on July 20, 2026, reporting first patient dosed in a Phase II NSCLC study of AK146D1 plus ivonescimab.
  • Trial will assess the TROP2/Nectin-4 bispecific ADC combination, with emphasis on the first-line setting.
  • Update supports Akeso’s “IO2.0 + ADC2.0” strategy as it advances next-generation ADC candidates into Phase II.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607200132PR_NEWS_USPR_____CN07721) on July 20, 2026, and is solely responsible for the information contained therein.